Previous 10 | Next 10 |
The European Medicines Agency accepted a marketing authorization application by CSL's (OTCPK:CSLLY) unit CSL Behring's for gene therapy etranacogene dezaparvovec (EtranaDez) to treat hemophilia B. Etranacogene dezaparvovec is administered as a one-time treatment for patients...
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B PR Newswire Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the...
uniQure (NASDAQ:QURE) completed patient enrollment in the first two cohorts of Phase I/II trial of its therapy, AMT-130, to treat early stage Huntington’s disease. The early-to-mid stage study includes two dose cohorts of 26 patients randomized to either treatment with the company...
LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its ...
uniQure (QURE +4.2%) is trading higher for the third straight session after UBS upgraded the shares of the Dutch biotech to Buy from Neutral, citing an attractive long-term risk-reward profile ahead of key milestones expected in the next 1 – 2 years. The analysts led by Eliana Merle po...
Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems...
uniQure press release (NASDAQ:QURE): FY GAAP EPS of $7.04 beats by $0.96. Revenue of $524M (+1297.0% Y/Y) beats by $56.66M. As of December 31, 2021, the Company had cash and cash equivalents of $556.3 million. For further details see: uniQure GAAP EPS of $7.04 beats by $0.96, revenue of...
~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy; Submissions of marketing applications on track for the first half of 2022...
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
News, Short Squeeze, Breakout and More Instantly...
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...